A Randomized, Double-blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Subjects With Cancer-Related Pain
Estudio aleatorizado, en doble ciego y controlado con placebo, para evaluar la seguridad y la eficacia de la metilnaltrexona subcutánea en el tratamiento del estreñimiento inducido por opiáceos...
Ontology highlight
ABSTRACT: Primary objectives: The objective of this study is to evaluate the efficacy and safety of sub-cutaneous methylnaltrexone in relieving opioid-induced constipation in subjects with cancer-related pain.
Primary endpoints: The primary endpoint is the proportion of subjects who have a rescue-free bowel movement within 4 hours after the first dose of study drug.
DISEASE(S): Opioid-induced Constipation In Subjects With Cancer-related Painestreñimiento Inducido Por Opiáceos En Pacientes Con Dolor De Origen Tumoral,Opioid-induced Constipation In Subjects With Cancer-related Pain
estreñimiento Inducido Por Opiáceos En Pacientes Con Dolor De Origen Tumoral,Constipation
PROVIDER: 2525209 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA